

Vorlesung Klappenerkrankungen

Mitralklappe Tricuspidalklappe




UniversitätsSpital
Zürich





Klappenerkrankungen


Prävalenz



Prognose








Mitralklappenerkrankungen

Mitralinsuffizienz


Mitralstenose

Ursachen der Mitralinsuffizienz

Verteilung der Ursachen nach Alter



Mitralklappe: Anatomie




Echokardiographie bei Mitralklappenerkrankungen


1D




2D





3D



A-mode




M-mode



FR 54Hz
16cm

2D
48%
C 50
P Low
HGen

M3



JPEG


70 bpm





FR 20Hz
15cm

2D
48%
C 50
P Low
HGen
CF
66%
2.5MHz
WF High
Med

M3 M4
+67.0



-67.0
cm/s




69 bpm

FR 66Hz
15cm

2D
45%
C 50
P Low
HGen

M3



JPEG

69 bpm




FR 22Hz
15cm

2D
47%
C 50
P Low
HGen
CF
66%
2.5MHz
WF High
Med

M3 M4
+67.0



-67.0
cm/s




66 bpm

FR 73Hz
17cm

2D
53%
C 50
P Low
HGen

M3





JPEG

66 bpm



FR 20Hz
17cm

2D
52%
C 50
P Low
HGen
CF
66%
2.5MHz
WF High
Med





FR 64Hz
9.0cm

2D
60%
C 50
P Off
Gen



M4



JPEG

73 bpm



PAT T: 37.0C
TEE T: 39.1C

FR 13Hz
9.0cm

2D
63%
C 50
P Off
Gen


CF
59%
4.4MHz
WF High
Med



M4 M4
+61.6



-61.6
cm/s



PAT T: 37.0C
TEE T: 39.1C

JPEG

73 bpm

FR 32Hz
8.1cm

Full Volume
3D 31%
3D 40dB



M4



JPEG

73 bpm


PAT T: 37.0C
TEE T: 38.0C

FR 32Hz
8.1cm

Full Volume 0 65 180
3D 31%
3D 40dB







M4







PAT T: 37.0C
TEE T: 38.0C

JPEG

73 bpm






FR 19Hz
8.1cm


Full Volume

3D 36%
3D 40dB

CF
50%
4.4MHz



M4 M4
+61.6



PAT T: 37.0C
TEE T: 38.1C

JPEG

72 bpm

FR 19Hz

8.1cm

Full Volume

3D 36%

3D 40dB


CF

50%


4.4MHz



M4 M4
+61.6







-61.6





PAT T: 37.0C
TEE T: 38.1C

JPEG


72 bpm



Hämodynamik der Mitralinsuffizienz



Folgen der Mitralsuffizienz



Mitralinsuffizienz und kardiale Funktion

Linker Ventrikel:

**Volumenüberlastung
Progressive Dilatation
Myokardiale Hypertrophie
Systolische Dysfunktion
Ventrikuläre Arrhythmien**



Linker Vorhof:

**Progressive Dilatation
Atriale Arrhythmien
Atriale Thromben**

Sekundäre pulmonale Hypertonie

Mitralinsuffizienz

Untersuchung von Patienten mit MI



1: normal

2: normal

Holosystolisches Geräusch, bandförmig, fauchend

Ausstrahlung in Axilla, v. a. in Linksseitenlage

3: häufig vorhanden

MKP: systolischer Click und daran anschliessend MI

Palpation:

Herz: Hebender lateralisierter Herzspitzenstoss, eventuell systolisches Schwirren

Puls: Häufig unregelmässig wegen VHF

Arterieller Blutdruck:

Normale Amplitude



EKG:

Sinusrhythmus (VHF); Linkslage; Linkshypertrophie; Repolarisationsstörung


Mitralinsuffizienz

Untersuchung von Patienten mit MI




Auskultationsort	Schematische phonokardiografische Darstellung	Key point
 p.m.: Herzspitze	 A P 1. HT 2. HT 3. HT 4. HT	Herztöne: 1. HT leise oder fehlend, 2. HT breit gespalten Extratöne: 3. HT Herzgeräusche: hochfrequentes, holosystolisches, band- förmiges Geräusch

Mitralklappe: Prolaps



Formen der Mitralinsuffizienz

			
Type I Normal leaflet motion Type II Increased leaflet motion Type IIIa Restricted leaflet motion (systole and diastole) Type IIIb Restricted leaflet motion (systole)			
	Primary Mitral Regurgitation	Secondary Mitral Regurgitation	
Prognosis	Primarily dependent on the severity of mitral regurgitation and secondarily on left and right ventricular function and pulmonary pressures	Primarily dependent on the degree of underlying left ventricular dysfunction and secondarily on the severity of mitral regurgitation	
Principal management strategy (standard of care)	Mitral valve surgery when severe (repair preferred to replacement); MitraClip may be considered in patients at prohibitive surgical risk with appropriate anatomy	GDMT for heart failure ± cardiac resynchronization therapy ± coronary revascularization when indicated; mitral valve surgery (repair or replacement) is not common clinical practice but may be considered in selected cases	



Primäre Mitralinsuffizienz

FR 38Hz
14cm

xPlane
65%
65%
44dB
P Off
Gen



M4



PAT T: 37.0C
TEE T: 38.8C

70 bpm

FR 9Hz
14cm



xPlane
68%
68%
44dB
P Off
Gen



M4 M4

+61.1
-61.1
cm/s

CF
59%
4.4MHz
WF High
Med



PAT T: 37.0C
TEE T: 38.7C

68 bpm

FR 21Hz
14cm

Full Volume
3D 36%
3D 32dB



M4



JPEG

70 bpm


PAT T: 37.0C
TEE T: 38.3C

FR 21Hz
14cm

Full Volume
3D 36%
3D 32dB



M4



JPEG

70 bpm


PAT T: 37.0C
TEE T: 38.3C

Quantifizierung der Mitralinsuffizienz

	MR severity*		
	Mild	Moderate	Severe
Structural			
MV morphology	None or mild leaflet abnormality (e.g., mild thickening, calcifications or prolapse, mild tenting)	Moderate leaflet abnormality or moderate tenting	Severe valve lesions (primary: flail leaflet, ruptured papillary muscle, severe retraction, large perforation; secondary: severe tenting, poor leaflet coaptation)
LV and LA size [†]	Usually normal	Normal or mild dilated	Dilated [‡]
Qualitative Doppler			
Color flow jet area [§]	Small, central, narrow, often brief	Variable	Large central jet (>50% of LA) or eccentric wall-impinging jet of variable size
Flow convergence	Not visible, transient or small	Intermediate in size and duration	Large throughout systole
CWD jet	Faint/partial/parabolic	Dense but partial or parabolic	Holosystolic/dense/ triangular
Semiquantitative			
VCW (cm)	<0.3	Intermediate	≥0.7 (>0.8 for biplane) [¶]
Pulmonary vein flow [#]	Systolic dominance (may be blunted in LV dysfunction or AF)	Normal or systolic blunting [#]	Minimal to no systolic flow/ systolic flow reversal
Mitral inflow ^{**}	A-wave dominant	Variable	E-wave dominant (>1.2 m/sec)
Quantitative ^{††,‡‡}			
EROA, 2D PISA (cm ²)	<0.20	0.20-0.29	0.30-0.39
			≥0.40 (may be lower in secondary MR with elliptical ROA)
RVol (mL)	<30	30-44	45-59 ^{††}
			≥ 60 (may be lower in low flow conditions)
RF (%)	< 30	30-39	40-49
			≥50


Prognose der schweren Mitralinsuffizienz

1-Jahres-Ueberleben von symptomatischen Patienten



90% 1-Jahres-Ueberleben (schwer, symptomatisch, keine Intervention)


Therapie der primären schweren Mitralinsuffizienz



Sekundäre Mitralinsuffizienz

FR 17Hz
14cm

Full Volume 0 55 180
3D 52%
3D 52dB
CF
71%
4.4MHz




M4 M4
+61.1



FR 17Hz
14cm

Full Volume 0 55 180
3D 37%
3D 40dB
CF
71%
4.4MHz



M4 M4
+61.1



JPEG





70 bpm

JPEG

70 bpm

PAT T: 37.0C
TEE T: 38.6C

PAT T: 37.0C
TEE T: 38.6C



Therapie der sekundären schweren Mitralinsuffizienz

Recommendations	Class ^b	Level ^c
Surgery is indicated in patients with severe secondary mitral regurgitation undergoing CABG and LVEF >30%.	I	C
Surgery should be considered in symptomatic patients with severe secondary mitral regurgitation, LVEF <30% but with an option for revascularization and evidence of myocardial viability.	IIa	C
When revascularization is not indicated, surgery may be considered in patients with severe secondary mitral regurgitation and LVEF >30% who remain symptomatic despite optimal medical management (including CRT if indicated) and have a low surgical risk.	IIb	C
When revascularization is not indicated and surgical risk is not low, a percutaneous edge-to-edge procedure may be considered in patients with severe secondary mitral regurgitation and LVEF >30% who remain symptomatic despite optimal medical management (including CRT if indicated) and who have a suitable valve morphology by echocardiography, avoiding futility.	IIb	C
In patients with severe secondary mitral regurgitation and LVEF <30% who remain symptomatic despite optimal medical management (including CRT if indicated) and who have no option for revascularization, the Heart Team may consider a percutaneous edge-to-edge procedure or valve surgery after careful evaluation for a ventricular assist device or heart transplant according to individual patient characteristics.	IIb	C

No conclusive evidence for survival benefit after mitral valve intervention

Mitral valve intervention recommended when there is an indication for CABG

Mitral valve intervention without CABG can be considered when the patient is symptomatic despite optimal medical therapy and CRT


MitraClip can be considered in patients at high surgical risk

Mitralinsuffizienz und konventionelle Chirurgie

Table 1 | MV lesions differentiated by complexity* and surgical requirements for MV repair

	Simple lesions	Complex lesions	Lesions at high-risk of unsuccessful repair
Type of lesion	Posterior leaflet prolapse or flail (isolated mid-scallop involvement [P2], with or without redundant tissue [leaflet height ≥ 15 mm]) Annular dilation Leaflet perforation	Complex posterior leaflet lesions Anterior prolapse or flail Bileaflet prolapse or flail Commissural prolapse or flail Combined lesions Deviant anatomy	Prolapse and extensive annular calcification Prolapse with hypoplasia of opposite leaflet Extreme fibroelastic deficiency Post-endocarditis extensive destruction Rheumatic disease
Probability of successful and durable repair	High	Depends on experience of the surgical team	Low
Surgical techniques	Quadrangular or triangular resection (including sliding plasty according to leaflet height) Annuloplasty Patch or direct suture	Artificial chordae Chordal transposition Edge-to-edge technique	Very technically demanding techniques (including artificial chordae, leaflet enlargement, and annular decalcification)
Necessary expertise of surgical team	Low	High	Very high
*Judged by echocardiography. Abbreviation: MV, mitral valve.			

Mitralinsuffizienz und perkutane Rekonstruktion



Mitralinsuffizienz und medikamentöse Therapie

- **Betablocker: keine Daten**
- **Diuretika, Nitrate: kontroverse Daten**
Ausgenommen: akute Mitralinsuffizienz
- **Arterielle Hypertonie behandeln**
- **Gegebenenfalls Herzinsuffizienz behandeln**
- **Antikoagulation:**
 - **bei VHF und bei Thrombus im LA**
 - **für 3 Monate nach MKR**